64 results about "Elevated blood glucose level" patented technology

The present invention relates to compounds of Formula (I),methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury / loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.

The present invention relates to compounds of Formula (I),methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury / loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.

The present invention provides antibodies that bind to the human glucagon receptor, designated GCGR and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human GCGR. The antibodies of the invention are useful for lowering blood glucose levels and blood ketone levels and are also useful for the treatment of diseases and disorders associated with one or more GCGR biological activities, including the treatment of diabetes, diabetic ketoacidosis, long-term complications associated with diabetes, or other metabolic disorders characterized in part by elevated blood glucose levels, including stress hyperglycemia.

The present invention relates to compounds of Formula (I),methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury / loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.

The invention belongs to the technical field of medicine-food homologous formula food and particularly relates to special diet for hyperglycemia patients. The reason inducing hyperglycemia is that hepatic glycogen output is increased, too much high-fat food is ingested, the pancreatic islet function can not excellently secrete insulin, and then, the blood sugar content is increased. The traditional Chinese medical science always stresses that dietotherapy is better than medication, so as to avoid injection and medication and even pain of surgery. According to the special diet, whole grains are perfectly combined with medicine-food homologous and new-resource-food traditional Chinese medicines, and diet and health preserving are organically combined so as to regulate, prevent and resist hyperglycemia; probiotics are creatively utilized as a pioneer based on the inheritance of Chinese traditional Chinese medicine treasure treatment methods, and the proliferation of the probiotics is promoted, so that the movement functions of the spleen and stomach are enhanced; and meanwhile, various natural and original ecological medicine-food homologous edible materials are added according to the physical characteristics of hyperglycemia patients, so that the special diet has the unique advantage of integrated dietotherapy, prevention and regulation effects.

The present invention provides antibodies that bind to the human glucagon receptor, designated GCGR and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human GCGR. The antibodies of the invention are useful for lowering blood glucose levels and blood ketone levels and are also useful for the treatment of diseases and disorders associated with one or more GCGR biological activities, including the treatment of diabetes, diabetic ketoacidosis, long-term complications associated with diabetes, or other metabolic disorders characterized in part by elevated blood glucose levels, including stress hyperglycemia.

The present invention provides antibodies that bind to the human glucagon receptor, designated GCGR and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human GCGR. The antibodies of the invention are useful for lowering blood glucose levels and blood ketone levels and are also useful for the treatment of diseases and disorders associated with one or more GCGR biological activities, including the treatment of diabetes, diabetic ketoacidosis and long-term complications associated with diabetes, or other metabolic disorders characterized in part by elevated blood glucose levels.

The present invention relates to compounds of Formula (I),methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury / loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.

The invention relates to a medicated chicken meatball and a preparation method thereof. The medicated chicken meatball is processed and made according to the following raw materials in parts and mix proportion by weight: 50-70 parts of chicken breast meat, 20-30 parts of chicken skin, 5-10 parts of yam flour, 5-10 parts of hawthorn powder, 60-80 parts of starch, 3-6 parts of salt, 1.5-3 parts of white sugar, 0.1-0.3 part of monosodium glutamate, 1-1.5 parts of phosphate, 0.04-0.1 part of carrageeenen, 0.01-0.04 part of ball gelatin, 0.2-0.4 part of shallot powder, 0.1-0.2 part of ginger powder, 1-3 parts of soy sauce, 100-120 parts of ice water and 1-3 parts of sesame oil. Since the food materials of hawthorn and yam which belong to the homology of medicine and food contained in the product, lipid dissolution, blood-lipid lowering, blood vessel extension, blood pressure lowering, suppression of blood-glucose elevation after meal and promotion of gastric and intestinal digestion can be effectively realized, and the efficacies of invigorating the spleen and nourishing the stomach are provided. The nutritional ingredients of the product is guaranteed to the maximum extent due to the adoption of the cooking approaches of steaming and boiling, and the product has the characteristics of unique mouthfeel, simpleness in processing, convenience for eating, nutrition, wholesomeness and the like, thereby being convenient for industrialized production and popularization.

The invention discloses a food formula special for patients suffering from diabetes and a preparation method thereof. The food formula is characterized in that food comprises the following substances in percentage by weight: 35.1 to 42.9 percent of carbohydrates, 14.7 to 17.9 percent of protein (a ratio of plant protein to animal protein is 1:3), 7.8 to 9.6 percent of fat (the content of saturated fatty acid in plant fat is less than 10 percent), 18 to 22 percent of dietary fibers, 9 to 11 percent of sweeteners (xylitol, maltitol, sorbitol and other sweeteners which do not cause blood sugar rising), 4.5 to 5.5 percent of cinnamomvine powder and coix seed powder (1:1) and 0.9 to 1.1 percent of additives (pigment, essence, vitamin and trace elements). The substances are mixed in the ratio to form a mixture with nutrition which is required by the patients suffering from the diabetes, and the mixture is made into the food such as nutritional powder, cookies, caramel treats, moon cakes, bread, candies and the like which are suitable to be eaten by the patients suffering from the diabetes every day. After the food is eaten by the patients suffering from the diabetes for a long time, the nutrition is balanced, and metabolic disorder and complications are reduced. In addition, the edible amount of the patients are easy to control, the weight is reduced, the physique is restored, the insulin resistance and hypertension are improved, and the using amount of blood sugar-reducing medicaments is reduced.

A therapeutic or an edible composition comprising at least three of the five herbs selected from Prunus amygdales, Ocimum sanctum, Azadirachta indica, Aegle marelose and Vitus vinefera, is provided for the treatment of hyperglycemia, especially for non-insulin dependent diabetic subjects, and the herbal composition has significantly reduced the blood glucose levels in both diabetic and non-diabetic experimental subjects having elevated blood glucose levels.

Inorganic anions nitrate and nitrite influence metabolic rate and glucose homeostasis. Infusion of nitrite iv caused an acute drop in resting energy expenditure (oxygen consumption) and nitrate, when given perorally, caused a drop in oxygen consumption during exercise and a depression of the increase in blood glucose observed after an oral glucose tolerance test. The doses of nitrate and nitrite did not cause any detectable change in methemoglobin levels of blood. Also, nitrate and nitrite did not alter lactate levels in blood. This discovery provides useful treatments to regulate the energy expenditure and glucose homeostasis of a mammal by administration of inorganic nitrite and / or nitrate.

The invention provides a fruit beverage facilitating reduction of uric acid and belongs to the technical field of fruit beverages. The fruit beverage comprises components in parts by mass as follows 10-20 parts of cherry powder, 10-20 parts of hawthorn fruit powder, 1-10 parts of tomato powder, 1-5 parts of mulberry leaf powder, 1-10 parts of resistant dextrin, 1-5 parts of vitamin C, 20-50 parts of erythritol, 0.5-1 part of konjac flour, 0.05-0.1 parts of sucralose and 0.5-1 part of tricalcium phosphate. The fruit beverage is suitable for patients suffering from gout, facilitates reduction of uric acid, relieves symptoms of gout, tastes palatably acid and sweet and can promote secretion of saliva and improve the appetite. Noncaloric erythritol is added to the beverage and matched with sucralose, so that the beverage tastes palatably sweet and cannot cause dental decay or rising of blood glucose.

The invention discloses a pharmaceutical composition for control of diabetes and complications thereof. The pharmaceutical composition comprises: sea cucumber polypeptide, alginate oligosaccharide, a kudzu vine root extract, a common duckweed extract, a radix trichosanthis extract, an extract of peach kernel and safflower, a ginkgo leaf extract, hirudin and nattokinase. The pharmaceutical composition provided by the invention can treat insulin resistant diabetes, the effective components are compounded to achieve better prevention and treatment effect on diabetes than single component, and the pharmaceutical composition also can prevent and treat some chronic complications associated with blood glucose rise. The pharmaceutical composition provided by the invention has the advantages of simple production process, low cost, high benefit, and obvious economic and social benefits.

The invention relates to a functional food and particularly relates to a composition capable of reducing blood glucose. The composition capable of reducing blood glucose comprises 95-98 parts of water-soluble dietary fibers (resistance dextrin), 1.5-3 parts of L-arabinose and 0.5-2 parts of jade plant powder. Compared with the prior art, the composition has the advantages that the water-soluble dietary fibers (resistance dextrin) can relieve or eliminate the sense of hunger for diabetics, can improve the physical energy and is significant in blood glucose and urine glucose reduction effect, simultaneously, the L-arabinose and the jade plant powder in the composition are also significant in blood glucose reduction effect, the blood glucose can be reduced further, the postprandial blood glucose rising can be restrained significantly after the composition is taken, and the composition can achieve a unique prophylaxis and treatment effect for complications caused by diabetes mellitus.

The invention relates to the field of foods, and particularly relates to nutrition powder for improving the blood glucose, blood lipid and intestinal environment. The nutrition powder is prepared fromthe following components in parts by weight: 25-67 parts of inulin, 25-70 parts of highland barley, 1-10 parts of a mulberry leaf extract, 1-10 parts of a balsam pear extract and 1-10 parts of tartary buckwheat. The nutrition powder can be used for effectively reducing the blood glucose and blood lipid of the population with hyperlipidemia, hypertension and hyperglycemia, improving intestinal functions of people, reducing constipation and improving the blood glucose level of a hypoglycemia population, enables the blood glucose level of the hypoglycemia population to be close to an optimal level value, can improve complications of weakening gastrointestinal functions of diabetic patients while improving the blood glucose concentration of the diabetic patients, and keeps the blood glucose level of the diabetic patients in a stable state.

The present invention is medicinal use of mulberry leaf flavonid, and features that mulberry leaf flavonid is used in medicine for treating insulin resistance disease. Intracorporeal and extracorporeal experiments show that mulberry leaf flavonid has excellent effect of treating insulin resistance disease, and possesses obvious effect of improving insulin resistance, improving blood sugar raising caused by insulin resistance and raising the insulin sensitivity of type II diabetics, low toxicity, less side effect and high use safety.

The present application describes a composition for blood glucose control containing green tea extracts (GTE) with gallated catechins (GC) and macromolecule to prevent the intestinal absorption of GC.

A health-care food for regulating blood sugar and immunity is prepared from the extracts of wolfberry fruit, tea, pueraria root and grape seed, and taurine.

The invention provides blood sugar controlling candies. The blood sugar controlling candies contain 5-10wt% of a blood sugar controlling agent. According to the blood sugar controlling candies disclosed by the invention, L-arabinose and tagatose are compounded, so that the absorption of cane sugar and glucose is blocked, postprandial hyperglycemia is restrained, and the occurrence of diabetes is avoided. When diabetic patients eat the blood sugar controlling candies during hypoglycemia, the sugar content can be provided timely, the blood sugar cannot rise too much and too fast, smooth blood sugar can be maintained, the pancreas burden is not increased, the smooth state of an illness is maintained, the physical health of the diabetic patients is facilitated, and besides, the diabetic patients can enjoy delicious foods.

The invention discloses ginseng peptide with an auxiliary blood glucose lowering effect and a preparation method thereof. The ginseng peptide with the auxiliary blood glucose lowering effect is mainlyprepared from the following components in parts by weight: 40 to 55 parts of ginseng peptide, 15 to 17 parts of bitter gourd, 12 to 15 parts of radix aconiti preparata, 13 to 16 parts of radix aconiti kusnezoffii praeparata, 12 to 14 parts of fructus chaenomelis, 18 to 20 parts of garcinia cambogia peel, 12 to 14 parts of fructus mume, 10 to 15 parts of herba taraxaci, 1 to 3 parts of vitamin D,6 to 8 parts of fructus coriandri, 6 to 10 parts of seaweed, 15 to 19 parts of globe amaranth flower and 13 to 17 parts of rhizoma polygonati. According to the ginseng peptide with the auxiliary bloodglucose lowering effect, provided by the invention, all raw materials have a synergistic effect to lower blood glucose; the auxiliary treatment effect of the ginseng peptide provided by the inventionon patients with diabetes mellitus is improved and a condition that nutritional components of organisms are lacked, caused by the fact that the blood glucose of the patients with the diabetes mellitus is raised, is improved; the enzymolysis efficiency and the enzymolysis degree are high through the combination of enzymes in enzymolysis and the selection of the dosage; the variety and quantity ofamino chemicals in an enzymolysis product are great and the mouthfeel is good.

The present invention relates to a complex sugar alcohol inhibiting alpha-glucosidase and reducing food GI value, and the complex sugar alcohol comprises erythritol, trehalose and / or isomaltitol. Thepresent invention also relates to use of the complex sugar alcohol in preparation of a food product for reducing the food GI value. The complex sugar alcohol can effectively inhibit the activity of alpha-glucosidase, effectively inhibits increase of blood sugar caused by ingestion of sucrose, can be added as a food additive to food which is rich in sucrose, starch, and the like, and has high tendency to induce blood sugar increase in human body, and is very suitable for diabetics to eat.

The present invention relates to compounds of Formula (I),methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury / loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.

The invention provides a method for constructing a diabetic nephropathy animal model.The influence of environmental pollution on disease occurrence is simulated, cadmium chloride serves as an inductor of the diabetic nephropathy animal model, administration is mainly achieved through intraperitoneal injection, high glucose and high fat are combined for feeding for 8 weeks, the physiological and biochemical index detection result shows that cadmium chloride can cause rise of blood glucose and increase of the NAG content, and pathological examinations meet the pathological change of diabetic nephropathy.The method has the advantages of being easy to operate, economical, high in model making success rate and the like, the pathogenic process of diabetic nephropathy can be simulated, and the problem that an existing diabetic nephropathy animal model is single is solved.

The present invention discloses a method to reduce elevated blood glucose levels in a subject, typically having (pre-)diabetes, steatohepatitis, obesity, and / or metabolic syndrome, when orally administered. Particularly preferred compositions include a set of active components consisting of two or more isolated and purified saccharides selected from galacturonic acid, glucuronic acid, galactose, arabinose, glucuronic acid, rhamnose, xylose, and mannose. The composition administered to a subject in need thereof an effective dose of the composition for a period of at least 6 weeks, wherein administration results in an at least 5% reduction of blood glucose.